Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 26.75
ALT's Cash-to-Debt is ranked lower than
55% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ALT: 26.75 )
Ranked among companies with meaningful Cash-to-Debt only.
ALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 9.09 Max: No Debt
Current: 26.75
0.03
No Debt
Equity-to-Asset 0.66
ALT's Equity-to-Asset is ranked higher than
76% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALT: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
ALT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.53  Med: 0.58 Max: 0.97
Current: 0.66
-0.53
0.97
Debt-to-Equity 0.01
ALT's Debt-to-Equity is ranked higher than
99% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ALT: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
ALT' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.51  Med: 0.26 Max: 7.61
Current: 0.01
-3.51
7.61
Debt-to-EBITDA -0.02
ALT's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ALT: -0.02 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.31  Med: -0.58 Max: -0.02
Current: -0.02
-1.31
-0.02
Piotroski F-Score: 4
Altman Z-Score: 7.68
Beneish M-Score: -0.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -359.76
ALT's Operating Margin % is ranked lower than
61% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ALT: -359.76 )
Ranked among companies with meaningful Operating Margin % only.
ALT' s Operating Margin % Range Over the Past 10 Years
Min: -359.76  Med: -97.15 Max: -24.89
Current: -359.76
-359.76
-24.89
Net Margin % 1447.76
ALT's Net Margin % is ranked higher than
100% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ALT: 1447.76 )
Ranked among companies with meaningful Net Margin % only.
ALT' s Net Margin % Range Over the Past 10 Years
Min: -166  Med: -79.1 Max: 3706.58
Current: 1447.76
-166
3706.58
ROE % 276.04
ALT's ROE % is ranked higher than
100% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ALT: 276.04 )
Ranked among companies with meaningful ROE % only.
ALT' s ROE % Range Over the Past 10 Years
Min: -453.67  Med: -76.43 Max: 1073.75
Current: 276.04
-453.67
1073.75
ROA % 151.19
ALT's ROA % is ranked higher than
100% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ALT: 151.19 )
Ranked among companies with meaningful ROA % only.
ALT' s ROA % Range Over the Past 10 Years
Min: -111.46  Med: -42.15 Max: 158.51
Current: 151.19
-111.46
158.51
ROC (Joel Greenblatt) % -2267.97
ALT's ROC (Joel Greenblatt) % is ranked lower than
70% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ALT: -2267.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6345.92  Med: -353.32 Max: -65.87
Current: -2267.97
-6345.92
-65.87
3-Year Revenue Growth Rate -39.10
ALT's 3-Year Revenue Growth Rate is ranked lower than
82% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALT: -39.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.1  Med: -29 Max: 173.1
Current: -39.1
-39.1
173.1
3-Year EBITDA Growth Rate -7.00
ALT's 3-Year EBITDA Growth Rate is ranked lower than
62% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALT: -7.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: -29.55 Max: 36
Current: -7
-66.7
36
GuruFocus has detected 3 Warning Signs with Altimmune Inc ALT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALT's 30-Y Financials

Financials (Next Earnings Date: 2018-03-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ALT Guru Trades in

Q1 2017

ALT Guru Trades in Q1 2017

Jim Simons 4,790,931 sh (New)
» More
Q2 2017

ALT Guru Trades in Q2 2017

Jim Simons 662,234 sh (-86.18%)
» More
Q3 2017

ALT Guru Trades in Q3 2017

Jim Simons 642,750 sh (-2.94%)
» More
» Details

Insider Trades

Latest Guru Trades with ALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:MIC:LIFE, NAS:AQB, OHEL:HRTIS, ROCO:6634, OSTO:PROMO, XSWX:ADXN, NAS:CTXR, XPAR:ALNOV, OTCPK:CRYO, NAS:ONS, ASX:IVQ, NAS:PULM, LSE:ETX, TSXV:CZO, TSX:CXR, XPAR:ALNEV, ASX:IMU, TSXV:BTI, OSTO:LIDDS, ASX:PBT » details
Traded in other countries:3G0N.Germany,
Headquarter Location:USA
Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It has two vaccine delivery platforms, RespirVec and Densigen.

Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include Nasovax, Heptcell, Sparvax-L, Nasoshield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

Top Ranked Articles about Altimmune Inc

Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors
Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors
Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study
Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial
Altimmune to Present at the 29th Annual Piper Jaffray Conference
Altimmune to Announce Third Quarter 2017 Financial Results on November 9
PharmAthene Reports First Quarter 2017 Financial and Operational Results
PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™

Total BARDA Five-Year Contract Value is $127.5 Million

GAITHERSBURG, Md., March 28, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutics company, today announced that the Company was awarded a contract modification to their previously announced contract. Under the U.S. Biomedical Advanced Research and Development Authority (BARDA) contract HHSO100201600008C, Altimmune has been awarded an additional $7.3 million for the manufacturing, scale up and testing of clinical materials to support planned clinical trials of NasoShield™, its first in class anthrax vaccine candidate. This increases the amount of the base contract performance period (July 2016 – July 2018) to $21.6 million and the total five-year contract value to $127.5 million, including options to receive up to $105.9 million to fund further pre-clinical, clinical and manufacturing development activities.  
NasoShield has been supported by BARDA, a division of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as a development stage medical countermeasure product and is designed to provide rapid, stable protection after one intranasal administration. In a head-to-head comparison with the existing approved anthrax vaccine in a gold-standard animal model, a single intranasal dose of NasoShield showed complete protection from inhaled anthrax and was non-inferior to multiple doses of the existing approved anthrax vaccine while providing for a more rapid and stable immune response. Scot Roberts Ph.D., Chief Scientific Officer of Altimmune, commented, “We are excited to be able to take our NasoShield program to the next level as we work to advance this program into clinical development. Our anthrax vaccine candidate has the potential to provide more rapid, stable and durable protection from a single intranasally administered dose, based on preclinical studies. We remain on track to file an IND with the FDA and commence a Phase 1 trial in early 2018.” The initial award under the BARDA contract will cover the GMP manufacture and the Phase 1 trial. The remainder of the five-year contract is expected to encompass a dose-selection Phase 1b study; scale-up in manufacturing; non-clinical studies; Phase 2 studies for immunogenicity, effectiveness and interactions with antibiotics; regulatory efforts; and formulation development to improve stability. About Altimmune
Altimmune is a clinical stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines. Using these technologies, Altimmune has developed three novel clinical stage product candidates that potentially represent an entirely new approach to harnessing the immune system. The Company’s most advanced product candidate, NasoVAX, is a Phase 2-ready intranasally-delivered recombinant influenza vaccine offering broad and rapid protection with potential for significant advantages over traditional flu vaccines. The second most advanced product candidate, HepTcell, is being tested as an immunotherapy for patients chronically infected with hepatitis B and has the potential to provide a functional cure. With the support of the U.S. Biomedical Advanced Research and Development Authority, or BARDA, the Company is developing a third product candidate, NasoShield, a first-in-class anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. The Company intends to leverage the RespirVec and Densigen platforms to develop additional product candidates for a variety of indications. On January 19, 2017, the Company announced the signing of a definitive agreement to merge with PharmAthene, Inc. (:PIP) in an all-stock transaction. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs.
Contacts:
Investor Relations
Matthew Duffy
LifeSci Advisors, LLC
Phone: 212-915-0685
Email: [email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 0.07
ALT's PE Ratio is ranked higher than
99% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. ALT: 0.07 )
Ranked among companies with meaningful PE Ratio only.
ALT' s PE Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.21 Max: 14.81
Current: 0.07
0.06
14.81
PE Ratio without NRI 0.07
ALT's PE Ratio without NRI is ranked higher than
99% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. ALT: 0.07 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.06  Med: 0.21 Max: 14.81
Current: 0.07
0.06
14.81
Price-to-Owner-Earnings 0.18
ALT's Price-to-Owner-Earnings is ranked higher than
99% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. ALT: 0.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.13  Med: 0.23 Max: 0.95
Current: 0.18
0.13
0.95
PB Ratio 0.60
ALT's PB Ratio is ranked higher than
98% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALT: 0.60 )
Ranked among companies with meaningful PB Ratio only.
ALT' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 5.71 Max: 31.02
Current: 0.6
0.42
31.02
PS Ratio 1.50
ALT's PS Ratio is ranked higher than
78% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ALT: 1.50 )
Ranked among companies with meaningful PS Ratio only.
ALT' s PS Ratio Range Over the Past 10 Years
Min: 0.44  Med: 3.24 Max: 52.45
Current: 1.5
0.44
52.45
Price-to-Free-Cash-Flow 0.05
ALT's Price-to-Free-Cash-Flow is ranked higher than
99% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. ALT: 0.05 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.93
Current: 0.05
0.04
0.93
Price-to-Operating-Cash-Flow 0.05
ALT's Price-to-Operating-Cash-Flow is ranked higher than
99% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. ALT: 0.05 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.93
Current: 0.05
0.04
0.93
EV-to-EBIT -0.32
ALT's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ALT: -0.32 )
Ranked among companies with meaningful EV-to-EBIT only.
ALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.4  Med: -6.1 Max: 15.5
Current: -0.32
-31.4
15.5
EV-to-EBITDA -0.32
ALT's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ALT: -0.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34  Med: -6.6 Max: 15.7
Current: -0.32
-34
15.7
EV-to-Revenue 1.05
ALT's EV-to-Revenue is ranked higher than
74% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ALT: 1.05 )
Ranked among companies with meaningful EV-to-Revenue only.
ALT' s EV-to-Revenue Range Over the Past 10 Years
Min: -29.6  Med: 3.25 Max: 37.3
Current: 1.05
-29.6
37.3
PEG Ratio 0.02
ALT's PEG Ratio is ranked higher than
99% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. ALT: 0.02 )
Ranked among companies with meaningful PEG Ratio only.
ALT' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: N/A
Current: 0.02
Current Ratio 6.25
ALT's Current Ratio is ranked lower than
60% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALT: 6.25 )
Ranked among companies with meaningful Current Ratio only.
ALT' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.87 Max: 389.51
Current: 6.25
0.41
389.51
Quick Ratio 6.25
ALT's Quick Ratio is ranked lower than
57% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ALT: 6.25 )
Ranked among companies with meaningful Quick Ratio only.
ALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.87 Max: 389.51
Current: 6.25
0.41
389.51
Days Sales Outstanding 92.04
ALT's Days Sales Outstanding is ranked lower than
92% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ALT: 92.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.98  Med: 38.72 Max: 130.76
Current: 92.04
3.98
130.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
ALT's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ALT: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33.9  Med: -19.9 Max: -4.2
Current: -9
-33.9
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 45.50
ALT's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ALT: 45.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.44  Med: 7.35 Max: 68.75
Current: 45.5
1.44
68.75
Price-to-Tangible-Book 30.33
ALT's Price-to-Tangible-Book is ranked lower than
83% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ALT: 30.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.44  Med: 7 Max: 40
Current: 30.33
1.44
40
Price-to-Intrinsic-Value-Projected-FCF 0.09
ALT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. ALT: 0.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.09  Med: 0.2 Max: 4.56
Current: 0.09
0.09
4.56
Price-to-Median-PS-Value 0.46
ALT's Price-to-Median-PS-Value is ranked higher than
50% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALT: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.02 Max: 28.87
Current: 0.46
0.21
28.87
Price-to-Graham-Number 0.30
ALT's Price-to-Graham-Number is ranked higher than
98% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. ALT: 0.30 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.21  Med: 0.59 Max: 3.08
Current: 0.3
0.21
3.08
Earnings Yield (Greenblatt) % -348.50
ALT's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ALT: -348.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -510.1  Med: -15.9 Max: 33.3
Current: -348.5
-510.1
33.3

More Statistics

Revenue (TTM) (Mil) $11.51
EPS (TTM) $ 28.09
Beta1.07
Short Percentage of Float6.13%
52-Week Range $1.51 - 35.00
Shares Outstanding (Mil)1.17

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}